SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CTI BioPharma Corp. (CTIC)

NEW YORK, Feb. 8, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of CTI BioPharma Corp. ("CTI" or the "Company") CTIC. Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.

This investigation concerns whether CTI BioPharma Corp. and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

On February 8, 2016, pre-market, CTI revealed that it had been notified by the U.S. Food and Drug Administration (FDA) that the FDA had placed a partial hold on clinical studies of CTI's main product, pacritinib.  The FDA has recommended that CTI adjust its protocols for randomized studies to disallow crossover to pacritinib, provide certain notifications, revise certain statements in the investigator's brochure and informed consent documents and other actions. 

Following this news, CTI stock fell $0.72, or nearly 65%, to just $0.40 per share during pre-market trading on February 8, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of CTI BioPharma Corp., you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!ctic/q62aa. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-cti-biopharma-corp-ctic-300216546.html

SOURCE Bronstein, Gewirtz & Grossman, LLC